The Vascular Endothelial Growth Factor Inhibitors Ranibizumab and Aflibercept Markedly Increase Expression of Atherosclerosis-Associated Inflammatory Mediators on Vascular Endothelial Cells-Reference-Cited by-同舟云学术

The Vascular Endothelial Growth Factor Inhibitors Ranibizumab and Aflibercept Markedly Increase Expression of Atherosclerosis-Associated Inflammatory Mediators on Vascular Endothelial Cells

Published:2016-03-09 Issue:3 Volume:11 Page:e0150688
ISSN:1932-6203
Container-title:PLOS ONE
language:en
Short-container-title:PLoS ONE

Author:

Arnott Clare,Punnia-Moorthy Gaya,Tan Joanne,Sadeghipour Sara,Bursill Christina,Patel Sanjay

Publisher

Public Library of Science (PLoS)

Subject

Multidisciplinary

Reference36 articles.

1. Ranibizumab for neovascular age-related macular degeneration;PJ Rosenfeld;N Engl J Med,2006

2. Development of ranibizumab, an anti-vascular endothelial growth factor antigen binding fragment, as therapy for neovascular age-related macular degeneration;N Ferrara;Retina,2006

4. The role of vascular endothelial growth factor in ocular health and disease;AP Adamis;Retina,2005

5. Prevalence of age-related macular degeneration in the United States;DS Friedman;Arch Ophthalmol,2004

Cited by 26 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Vascular Endothelial Growth Factor (VEGF) and Its Role in the Cardiovascular System;Biomedicines;2024-05-10

2. Sintilimab plus bevacizumab and CapeOx (BBCAPX) on first-line treatment in patients with RAS mutant, microsatellite stable, metastatic colorectal cancer: study protocol of a randomized, open-label, multicentric study;BMC Cancer;2023-07-18

3. Cardiovascular and Cerebrovascular Safety of Ranibizumab, Bevacizumab, and Aflibercept in Ocular Diseases: An Analysis of the US Food and Drug Administration Adverse Event Reporting System (FAERS) Database;The Journal of Clinical Pharmacology;2023-05-23

4. Risk analysis for patients with arterial thromboembolic events after intravitreal ranibizumab or aflibercept injections;Scientific Reports;2023-05-10

5. Advances in imaging and treatment of atherosclerosis based on organic nanoparticles;APL Bioengineering;2022-12-01